Anticancer Activity and Mechanism of Action Evaluation of an Acylhydrazone Cu(II) Complex toward Breast Cancer Cells, Spheroids, and Mammospheres
Abstract The purpose of this work was to screen the anticancer activity and mechanisms of action of Cu(II)‐acylhydrazone complex [Cu(HL)(H2 O)](NO3)⋅H2 O, (CuHL), to find a potential novel agent for breast chemotherapies. Cytotoxicity studies on MCF7 cells demonstrated that CuHL has stronger anticancer properties than cisplatin over breast cancer cell models. Computational simulations showed that CuHL could interact in the minor groove of the DNA dodecamer, inducing a significant genotoxic effect on both cancer cells from 0.5 to 1 μM. In this sense, molecular docking and molecular dynamics simulations showed that the compound could interact with 20S proteasome subunits. Also, cell proteasome experiments using breast cancer cells revealed that the complex can inhibit proteasomal activity. Moreover, CuHL induced apoptosis in breast cancer cells at very low micromolar concentrations (0.5–2.5 μM) and displayed relevant anticancer activity over spheroids derived from MCF7 cells. Ultimately, CuHL diminished the number of mammospheres formed, disturbing their morphology and size..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
ChemMedChem - 17(2022), 4 |
| Beteiligte Personen: |
Balsa, Lucia M. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley‐VCH GmbH |
|---|
| Umfang: |
13 |
|---|
| doi: |
10.1002/cmdc.202100520 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003683419 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003683419 | ||
| 003 | DE-627 | ||
| 005 | 20230307131026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cmdc.202100520 |2 doi | |
| 028 | 5 | 2 | |a CMDC_CMDC202100520.xml |
| 035 | |a (DE-627)WLY003683419 | ||
| 035 | |a (WILEY)CMDC202100520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 540 |a 610 |q ASE |
| 082 | 0 | 4 | |a 540 |a 610 |q ASE |
| 084 | |a 44.42 |2 bkl | ||
| 084 | |a 35.07 |2 bkl | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 1 | |a Balsa, Lucia M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anticancer Activity and Mechanism of Action Evaluation of an Acylhydrazone Cu(II) Complex toward Breast Cancer Cells, Spheroids, and Mammospheres |
| 264 | 1 | |c 2022 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley‐VCH GmbH | ||
| 520 | |a Abstract The purpose of this work was to screen the anticancer activity and mechanisms of action of Cu(II)‐acylhydrazone complex [Cu(HL)(H2 O)](NO3)⋅H2 O, (CuHL), to find a potential novel agent for breast chemotherapies. Cytotoxicity studies on MCF7 cells demonstrated that CuHL has stronger anticancer properties than cisplatin over breast cancer cell models. Computational simulations showed that CuHL could interact in the minor groove of the DNA dodecamer, inducing a significant genotoxic effect on both cancer cells from 0.5 to 1 μM. In this sense, molecular docking and molecular dynamics simulations showed that the compound could interact with 20S proteasome subunits. Also, cell proteasome experiments using breast cancer cells revealed that the complex can inhibit proteasomal activity. Moreover, CuHL induced apoptosis in breast cancer cells at very low micromolar concentrations (0.5–2.5 μM) and displayed relevant anticancer activity over spheroids derived from MCF7 cells. Ultimately, CuHL diminished the number of mammospheres formed, disturbing their morphology and size. | ||
| 700 | 1 | |a Rodriguez, Maria R. |4 aut | |
| 700 | 1 | |a Parajón‐Costa, Beatriz S. |4 aut | |
| 700 | 1 | |a González‐Baró, Ana C. |4 aut | |
| 700 | 1 | |a Lavecchia, Martin J. |4 aut | |
| 700 | 1 | |a León, Ignacio E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |g 17(2022), 4 |w (DE-627)WLY003672778 |x 18607187 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:4 |g extent:13 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.42 |q ASE |
| 936 | b | k | |a 35.07 |q ASE |
| 936 | b | k | |a 58.28 |q ASE |
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 4 |g 13 | ||